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1. INTRODUCTION {#mgg3994-sec-0005}
===============

Lung squamous cell carcinoma (LSqCC) is historically the most common type of lung cancer, particularly in developingMETH countries (Stone & Zhou, [2016](#mgg3994-bib-0035){ref-type="ref"}). The majority of stage I/II LSqCC patients undergo surgery with or without chemo‐ and/or radio‐therapy; while the majority of stage III/IV patients only receive chemotherapy and/or radiation therapy (Miller et al., [2016](#mgg3994-bib-0026){ref-type="ref"}). Based on Surveillance, Epidemiology, and End Results (SEER) data 2009--2013, the 5‐year survival rate for lung/bronchus cancer patients is 18.1%. For stage I/II LSqCC patients, the 5‐year survival is 34% (Takita et al., [1991](#mgg3994-bib-0040){ref-type="ref"}). For unresectable advanced LSqCC patients, the outcome is much worse.

Targeted therapy agents, such as epidermal growth factor receptor (EGFR) inhibitors and angiogenesis inhibitors, are important in the treatment of nonsmall cell lung cancer (NSCLC) (Yang et al., [2016](#mgg3994-bib-0045){ref-type="ref"}). In lung adenocarcinoma, patients with *EGFR* mutations could obtain survival benefits from EGFR inhibitors (Takano et al., [2008](#mgg3994-bib-0039){ref-type="ref"}), especially for "never smokers" (Sun et al., [2010](#mgg3994-bib-0037){ref-type="ref"}). However, targeting therapies are not efficacy for LSqCC patients, because LSqCC has distinct genetic alterations and biomarkers from lung adenocarcinoma (Campbell et al., [2016](#mgg3994-bib-0009){ref-type="ref"}; Paz‐Ares et al., [2016](#mgg3994-bib-0030){ref-type="ref"}; Seto et al., [2014](#mgg3994-bib-0033){ref-type="ref"}).

To explore potential targeting candidates for LSqCC treatment, genome‐wide analysis is recommended. Genome‐wide analysis has revealed that the majority region of the genome is transcribed into noncoding RNAs (ncRNAs); ncRNAs regulate the expression of other protein‐coding genes, but they themselves are not transcribed into proteins (Deniz & Erman, [2017](#mgg3994-bib-0012){ref-type="ref"}; Fu, [2014](#mgg3994-bib-0013){ref-type="ref"}). According to the transcript lengths, ncRNAs are categorized into small ncRNAs (sncRNAs) and long ncRNAs (lncRNAs) (Brosnan & Voinnet, [2009](#mgg3994-bib-0003){ref-type="ref"}). Classically, transfer RNAs, ribosomal RNAs, small nuclear RNAs, microRNAs, short interfering RNAs, and piwi‐interacting RNAs are sncRNAs (Taft, Pang, Mercer, Dinger, & Mattick, [2010](#mgg3994-bib-0038){ref-type="ref"}); exonic lncRNAs, intronic lncRNAs, overlapping lncRNAs, and intergenic lncRNAs (lincRNAs) are lncRNAs (Shi, Sun, Liu, Yao, & Song, [2013](#mgg3994-bib-0034){ref-type="ref"}).

LincRNAs play significant roles in human cancers (Deniz & Erman, [2017](#mgg3994-bib-0012){ref-type="ref"}; White et al., [2014](#mgg3994-bib-0044){ref-type="ref"}). For example, *TP53COR1* (*LincRNAp21)* functions as a tumor suppressor; it is down‐regulated in colorectal tumors (Zhai et al., [2013](#mgg3994-bib-0048){ref-type="ref"}), hepatocellular carcinoma (Yang et al., [2015](#mgg3994-bib-0046){ref-type="ref"}), prostate cancer (Isin et al., [2015](#mgg3994-bib-0022){ref-type="ref"}) and breast cancer (Chen et al., [2017](#mgg3994-bib-0011){ref-type="ref"}). *CYTOR* (*LINC00152)* overexpresses in pancreatic cancer (Muller et al., [2015](#mgg3994-bib-0027){ref-type="ref"}) and gastric cancer (Pang et al., [2014](#mgg3994-bib-0029){ref-type="ref"}). *LINC00673* regulates *PTPN11* and inhibits the proliferation of pancreatic cancer cells (Zheng et al., [2016](#mgg3994-bib-0049){ref-type="ref"}). In NSCLC cells, *LINC00673* promotes metastasis through EZH2 (Ma et al., [2017](#mgg3994-bib-0025){ref-type="ref"}). In this study, we used LSqCC samples from TCGA database to perform genome‐wide analysis for lincRNA transcripts. We found a panel of lincRNAs as candidates for predicting malignancies and poor prognosis, representing promising targets for anti‐LSqCC treatment.

2. Methods {#mgg3994-sec-0006}
==========

2.1. Database and cohort definition {#mgg3994-sec-0007}
-----------------------------------

The National Cancer Institute (NCI)‐supported harmonized cancer dataset TCGA‐LUSC transcriptome profiling was the data source in the present study. Sample description was extracted from metadata. 501 patients diagnosed with primary lung squamous cell carcinoma (sample site: C34.0‐C34.9; ICD‐O‐3 histology/behavior code: 8070/3, 8071/3, 8072/3, 8073/3, 8052/3 and 8083/3), with positive histology diagnostic confirmation were identified from TCGA‐LUSC project. As shown in Figure [S1](#mgg3994-sup-0001){ref-type="supplementary-material"}, of 501 included patients, 48 had paired primary tumor (PT) sample and solid normal (SN) tissue sample. Other 453 patients only had PT sample. To compare the transcriptional profiling of lincRNAs between SN and PT, paired test was performed in paired SN and PT samples. Additionally, 453 independent PT samples were compared to 48 independent SN samples. Definite tumor stage was reported in 497 patients, and 91 of them were in advanced stage (stage III/IV).

2.2. Statistical analysis for demographic and clinical‐pathological features {#mgg3994-sec-0008}
----------------------------------------------------------------------------

Information of demographic features (gender, gender, race, smoking history) and clinical‐pathological features (tumor stage, morphology, vital status, time to death, and time to last contact) were extracted from metadata and evaluated for included patients. Numeric variables were summarized as the mean (standard deviation) and median (interquartile range). Categorical variables were reported as counts (percentage). An analysis of variance was used to compare continuous variables with symmetric distributions across comparing subgroups. Chi‐square tests or Fisher\'s exact tests (*n* \< 5) were used to compare categorical variables between clinical/ pathological subgroups.

2.3. Transcriptional profiling {#mgg3994-sec-0009}
------------------------------

In RNA‐seq database, the gene expression level was recorded as fragments per kilobase of transcript per million mapped reads (FPKM). The gene expression information of a total of 60,483 genes from 549 samples with histological confirmation were extracted from TCGA‐LUSC project RNA‐seq database. By using Bioconductor package "org.Hs.eg.db", 36,095 genes were identified as protein coding genes, ncRNA genes and pseudogenes with approving unique symbols and names in HGNC (HUGO (Human Genome Organisation) gene nomenclature communnittee) database. 1,771 genes were recognized as lincRNA genes.

2.4. Predictive value of lincRNAs in diagnosis {#mgg3994-sec-0010}
----------------------------------------------

To screen out the potential candidates in discriminate primary tumor samples from solid normal samples, Wilcoxon two‐sample paired signed rank test was used to compare the expression of lincRNAs between 48 paired samples. In independent PT and SN samples, logistic regression analysis was performed to investigate the risk and protective lincRNAs of malignancies. Odds ratio (OR) with 95% confidence interval (CI) was calculated for each tested lincRNA. As for selected potential candidate lincRNAs, receiver operating characteristic (ROC) curve and the area under the curve (AUC) measured the efficiency in predicting malignancies.

To screen out potential lincRNAs in predicting advance tumors (stage III/IV), 497 independent PT samples with definite stage information were investigated. Logistic regression analysis was performed to evaluate the risk of advance stage for tested lincRNAs.

2.5. Prognosis analysis {#mgg3994-sec-0011}
-----------------------

Among 501 LSqCC patients, 285 were alive and censored. To identify the risk lincRNAs for cancer‐related death, the Cox proportional hazards regression was performed to estimate the hazard ratio (HR). A receiver operating characteristic (ROC) curve was calculated to determine the optimal cut‐off expression level of risk lincRNAs that maximizes sensitivity and specificity in predicting death. According to the cutoff values of risk lincRNAs, patients were divided into lincRNA high‐expression level subgroup and low‐expression level subgroup. Lifetest with Kaplan‐Meier curves were performed to compare the survival probabilities between lincRNA high level subgroup and low level subgroup.

2.6. Statistic tools {#mgg3994-sec-0012}
--------------------

Bioconductor packages were applied for RNA‐seq analysis. Package "RColorBrewer" and"ggplot\" were used for plotting. All tests of hypotheses were two‐tailed and conducted at a significance level of 0.05. Statistical analyses were conducted using R 3.3.2 and SAS 9.4.

3. RESULTS {#mgg3994-sec-0013}
==========

3.1. Demographic and clinical‐pathological features {#mgg3994-sec-0014}
---------------------------------------------------

As shown in Table [1](#mgg3994-tbl-0001){ref-type="table"}, among LSqCC 501 patients, 317 (74.05%) were males and 130 (25.95%) were females; 439 (89.95%) were white patients and 30 (7.73%) were African American patients; 222 (44.31%) patients had smoking history, and the average length of smoking (LOS) was 39.77 (±12.13) years. 406 (81.69%) patients were in early stages (stage I/II) and 91 (18.31%) were in late stages (stage III/IV). Compared to alive patients, deceased patients were older (67.84 ± 11.61 vs. 65.25 ± 13.42, *p* = .02), and more of them were African American patients (11.70% vs. 4.61%, *p* = .03).

###### 

Demographic and clinical‐pathological features of LSqCC patients

  Covariate                                                       Level                                   Overall patients (*n* = 501)   Survival status                                         
  --------------------------------------------------------------- --------------------------------------- ------------------------------ --------------------------- --------------------------- -----
  Age                                                                                                     66.37 ± 12.72, 68 (61,73)      65.25 ± 13.42, 67 (60,73)   67.84 ± 11.61, 69 (63,74)   .02
  Gender                                                          Male                                    371 (74.05%)                   204 (71.58%)                167 (77.31%)                .17
  Female                                                          130 (25.95%)                            81 (28.42%)                    49 (22.69%)                                             
  Race                                                            Asian                                   9 (2.34%)                      5 (2.30%)                   4 (2.34%)                   .03
  Black                                                           30 (7.73%)                              10 (4.61%)                     20 (11.70%)                                             
  White                                                           349 (89.95%)                            202 (93.09%)                   147 (85.96%)                                            
  Smoke                                                           Yes                                     222 (44.31%)                   132 (46.32%)                90 (41.67%)                 .30
  No                                                              279 (55.69%)                            153 (53.68%)                   126 (58.33%)                                            
  LOS\*                                                                                                   39.77 ± 12.13, 40 (30,50)      40 ± 11.36, 40 (32,50)      39.43 ± 13.23, 41 (30,50)   .73
  Stage                                                           I                                       244 (49.09%)                   144 (50.88%)                100 (46.73%)                .10
  II                                                              162 (32.60%)                            97 (34.28%)                    65 (30.37%)                                             
  III                                                             84 (16.90%)                             40 (14.13%)                    44 (20.56%)                                             
  IV                                                              7 (1.41%)                               2 (0.71%)                      5 (2.34%)                                               
  Morphology (ICD−0--3)                                           Squamous cell carcinoma, NOS (8070/3)   466 (93.01%)                   268 (94.04%)                198 (91.67%)                .07
  Squamous cell carcinoma, keratinizing (8071/3)                  13 (2.59%)                              3 (0.30%)                      10 (4.61%)                                              
  Squamous cell carcinoma, large cell, nonkeratinizing (8072/3)   3 (0.60%)                               2 (0.70%)                      1 (0.46%)                                               
  Squamous cell carcinoma, small cell, nonkeratinizing (8073/3)   1 (0.20%)                               0 (0.00%)                      1 (0.46%)                                               
  Papillary squamous cell carcinoma (8052/3)                      4 (0.80%)                               2 (0.70%)                      2 (0.93%)                                               
  Basaloid squamous cell carcinoma (8083/3)                       14 (2.79%)                              10 (3.51%)                     4 (1.85%)                                               

LOS\* indicated the length of smoking year in patients who have smoking history.
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Cox proportional hazard regression analyses were performed to evaluate the risk factors for mortality. Late stages (stage III/IV) were significant risk factor for mortality (HR (95% CI) = 1.527 (1.110, 2.103), *p* = .009, Table [S1](#mgg3994-sup-0004){ref-type="supplementary-material"}). Besides stage, African American patients had marginally higher hazards of mortality compared to white patients (HR (95% CI) = 1.578 (0.985, 2.527), *p* = .06, Table [S1](#mgg3994-sup-0004){ref-type="supplementary-material"}).

3.2. LincRNAs transcriptional profile of LSqCC samples {#mgg3994-sec-0015}
------------------------------------------------------

In independent LSqCC PT samples (*n* = 453) and SN tissue samples (*n* = 48), Logistic regression analysis showed that 72 (4%) lincRNAs were significant risk candidates for malignancies (OR \> 1, *p* \< .05), while 34 (2%) lincRNAs were significant protective candidates against malignancies (OR \< 1, *p* \< .05) (Figure [1](#mgg3994-fig-0001){ref-type="fig"}a). Figure [1](#mgg3994-fig-0001){ref-type="fig"}b listed 34 significant protective lincRNAs, and Figure [1](#mgg3994-fig-0001){ref-type="fig"}c listed 72 significant risk lincRNAs for malignancies. Here, OR (odds ratio) represented the times of odds of malignancies at 1 unit (FPKM) increase of gene expression. However, the expression levels of some lincRNAs in LSqCC samples were as low as 0.001 or even smaller. So, compared to their low expression levels, 1 unit (FPKM) increase might result in an extremely large or small OR. Therefore, we used the natural logarithm of OR (95% CI) \[logOR with log(95% CI lower limit) and log(95% CI lower limit)\] to narrow down the scale.

![Transcriptional profile of lincRNAs in LSqCC tumor samples and solid normal tissue samples. (a) Transcriptional profile of 1,771 LincRNAs was compared between independent primary tumor LSqCC samples and solid normal tissue samples. 72 (4%) lincRNAs were significant risk predictive candidates for malignancies (OR \> 1, *p* \< .05), while 34 (2%) lincRNAs were siginificant protective candidates against malignancies (OR \< 1, *p* \< .05). (b) Natural logarithm of OR and 95% CI of OR, logOR (95% CI), of 34 significant protective lincRNAs. (c) Natural logarithm of OR and 95% CI of OR, logOR (95% CI), of 72 significant risk lincRNAs. (d) Transcriptional profile in paired primary LSqCC tumor samples and solid normal tissue samples. Gene expression level of 23 (1.30%) lincRNAs were significantly higher in primary LSqCC tumor samples than matched solid normal tissue samples (*p* \< .05). The expression levels of 47 (2.65%) lincRNAs were significantly lower in primary tumors, compared to matched solid normal tissues (*p* \< .05). (e). The natural logarithm value of the gene expression ratio of PT versus SN samples (log(PT/SN)) of significant lincRNAs that overexpressed (red) or lower‐expressed (blue) in primary LSqCC tumors, compared to their paired solid normal tissue samples](MGG3-7-e994-g001){#mgg3994-fig-0001}

To further validate the risk/protective lincRNAs in predicting LSqCC, we compared the transcriptional profile of lincRNAs in 48 paired LSqCC PT samples and SN tissue samples by using Wilcoxon two‐sample paired signed rank test. As shown in Figure [1](#mgg3994-fig-0001){ref-type="fig"}d, the expression level of 23 (1.30%) lincRNAs were significantly higher in LSqCC PT samples, compared to the matched SN tissue samples (*p* \< .05); the expression levels of 47 (2.65%) lincRNAs were significantly lower in PT samples, compared to the matched SN tissues (*p* \< .05). Figure [1](#mgg3994-fig-0001){ref-type="fig"}e listed all he significant lincRNAs that overexpressed (red) or lowly‐expressed (blue) in LSqCC PT samples with the natural logarithm of their expression level of PT versus SN (log(PT/SN)). Among 23 highly‐expressed lincRNAs in primary tumor samples, 10 lincRNAs were significant risk candidates for malignancies in Logistic regression (Figure [1](#mgg3994-fig-0001){ref-type="fig"}c). These validated risk lincRNAs were *LINC00487*, *LINC01927*, *C10orf143* (*LINC00959*), *LINC01031*, *LINC01088*, *LINC01352*, *LINC01504*, *LINC01931*, *LINC01985,* and *LINC02395*. Among 47 lowly‐expressed lincRNAs in PT samples (blue, Figure [1](#mgg3994-fig-0001){ref-type="fig"}e), 10 lincRNAs were significant protective candidates against malignancies in Logistic regression (Figure [1](#mgg3994-fig-0001){ref-type="fig"}b). These validated protective factors were *LINC00307*, *LINC00491*, *LINC01063, LINC01385*, *LINC01448*, *LINC01524*, *LINC01697*, *LINC01719,* and *LINC02026*. The ORs (95% CIs) of above risk and protective lincRNAs for malignancies were listed in Table [2](#mgg3994-tbl-0002){ref-type="table"}.

###### 

Risk of lincRNAs for primary LSqCC tumor

  LincRNAs    Outcome: primary tumor               Outcome: advanced stage (stage III/IV)                                
  ----------- ------------------------------------ ---------------------------------------- ---------------------------- -----
  LINC00487   6.34E + 5 (109, 4.43E + 10)          .008                                     0.78 (0.09, 2.10)            .73
  LINC00959   4.85 (1.35, 21.78)                   .03                                      0.84 (0.38, 1.62)            .62
  LINC01031   65.71 (1.28, 1.97E + 4)              .04                                      0.66 (0.08, 2.35)            .63
  LINC01088   1.87 (1.02, 6.86)                    .05                                      0.99 (0.82, 1.09)            .88
  LINC01352   10.77 (1.66, 151.5)                  .04                                      0.65 (0.24, 1.46)            .34
  LINC01504   2.24 (1.01, 5.80)                    .05                                      0.86 (0.49, 1.42)            .57
  LINC01927   3.39E + 3 (16.00, 6.20E + 6)         .01                                      1.18 (0.16, 6.40)            .86
  LINC01931   2.22E + 30 (5.41E + 3, 7.28E + 66)   \<.0001                                  0.45 (5.83E−11, 6.60E + 4)   .91
  LINC01985   73.30 (1.85, 2.03E + 4)              .03                                      0.76 (0.13, 3.38)            .74
  LINC02395   5.89E + 36 (7.67E + 4, 8.80E + 82)   .02                                      0.01 (3.46E−15, 15.44)       .53
  LINC00307   0.02 (0.00, 0.55)                    .02                                      0.05 (1.97E−5, 7.14)         .35
  LINC00491   0.77 (0.62, 0.96)                    .02                                      0.85 (0.70, 1.03)            .12
  LINC01063   0.85 (0.76, 0.97)                    .01                                      0.90 (0.76, 1.05)            .21
  LINC01385   0.40 (0.18, 0.92                     .02                                      0.86 (0.32, 2.03)            .75
  LINC01448   0.22 (0.07, 0.79)                    .01                                      0.45 (0.05, 2.27)            .40
  LINC01524   0.07 (0.01, 0.59)                    .01                                      0.38 (0.01, 4.91)            .52
  LINC01697   0.71 (0.52, 1.00)                    .05                                      0.52 (0.26, 0.88)            .03
  LINC01719   0.42 (0.24, 0.75)                    .003                                     0.61 (0.27, 1.23)            .20
  LINC02026   0.48 (0.24, 0.99)                    .04                                      0.46 (0.15, 1.12)            .13
  LINC02315   0.84 (0.76, 0.92)                    .0002                                    1.01 (0.92, 1.11)            .81
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3.3. Predictive values of candidate lincRNAs in LSqCC diagnosis {#mgg3994-sec-0016}
---------------------------------------------------------------

To investigate the predictive value of the lincRNA candidates in LSqCC diagnosis, logistic regression with ROC curve was performed for twenty lincRNA candidates. The top three risk lincRNAs with the biggest area under ROC curve (AUC) values were selected out and integrated into a small joint panel A (*LINC00487* + *LINC01927* + *C10orf143* (*LINC00959*)). The top three protective lincRNAs with the biggest AUC values were selected out and integrated into a small joint panel B (*LINC02315* + *LINC00491* + *LINC01697*). The ROC curves were compared among the joint full model (all 20 lincRNA candidates), risk joint model (*LINC00487* + *LINC01927* + *C10orf143* (*LINC00959*)), protective joint model (*LINC02315* + *LINC00491* + *LINC01697*), and the risk/ protective combined model\*\* (*LINC00487* + *LINC01927* + *C10orf143* (*LINC00959*) + *LINC02315* + *LINC00491* + *LINC01697*). Figure [2](#mgg3994-fig-0002){ref-type="fig"}a showed that the AUC (95% CI) values for above four models were 0.8121 (95% CI = (0.7479, 0.8764)), 0.6885 (95% CI = (0.6209, 0.7561)), 0.6549 (95% CI = (0.5714, 0.7384)), and 0.7481 (95% CI = (0.6642, 0.8320)), respectively, in independent samples (nonpaired 453 PT samples and 48 solid SN samples). Figure [2](#mgg3994-fig-0002){ref-type="fig"}b showed that the AUC values for above four models were 0.9067 (95% CI = (0.8485, 0.9648)), 0.7274 (95% CI = (0.6264, 0.8285)), 0.7049 (95% CI = (0.6006, 0.4097)), and 0.8030 (95% CI = (0.7250, 0.8810)), respectively, in 48 pairs of PT samples and SN tissue samples. The sensitivities and specificities for above models in the independent samples and paired samples were listed in Table [S2](#mgg3994-sup-0005){ref-type="supplementary-material"}. The gene expression level (FPKM) of *LINC02315*, *LINC00491,* and *LINC01697* in independent PT samples (blue) and SN tissue samples (yellow) were shown in Figure [2](#mgg3994-fig-0002){ref-type="fig"}c. Boxplots in Figure [2](#mgg3994-fig-0002){ref-type="fig"}d showed the gene expression level (FPKM) of *LINC00487*, *LINC01927,* and *C10orf143* (*LINC00959*) in independent PT samples (red) and SN tissue samples (yellow). Table [S3](#mgg3994-sup-0006){ref-type="supplementary-material"} listed the statistical summary for actual gene expression levels (unit: FPKM).

![Predictive values of candidate lincRNAs in LSqCC diagnosis. (a) ROC curves for full model (20 lincRNA candidates), a small joint panel of risk lincRNAs (LINC00487 + LINC01927 + LINC00959), a small joint panel of protective lincRNAs (LINC02315 + LINC00491 + LINC01697), and joint model of risk and protective lincRNAs (model\*\*: LINC00487 + LINC01927 + LINC00959 + LINC02315 + LINC00491 + LINC01697) in independent samples (nonpaired 453 PT samples and 48 SN tissue samples). (b) ROC curves for full model (20 lincRNA candidates), a small joint panel of risk lincRNAs (LINC00487 + LINC01927 + LINC00959), a small joint panel of protective lincRNAs (LINC02315 + LINC00491 + LINC01697), and joint model of risk and protective lincRNAs (model\*\*: LINC00487 + LINC01927 + LINC00959 + LINC02315 + LINC00491 + LINC01697) in paired PT samples and 48 SN tissue samples. (c) The gene expression level of LINC02315, LINC00491 and LINC01697 in independent PT samples (blue) and SN tissue samples (yellow). (d) The gene expression level of LINC00487, LINC01927, and LINC00959 in independent PT samples (red) and SN tissue samples (yellow). (e) Predictive values of 10 protective lincRNA candidates in LSqCC staging. LogOR (95% CI) represents the natural logarithm transformation of OR (95% CI). (f) Predictive values of 10 risk lincRNA candidates in LSqCC staging. LogOR (95% CI) represents the natural logarithm transformation of OR (95% CI)](MGG3-7-e994-g002){#mgg3994-fig-0002}

3.4. Predictive values of LincRNAs in LSqCC staging {#mgg3994-sec-0017}
---------------------------------------------------

For patients in early stage (I/II), surgery provides the best chance for cure (Brunelli, Kim, Berger, & Addrizzo‐Harris, [2013](#mgg3994-bib-0006){ref-type="ref"}; Handforth et al., [2015](#mgg3994-bib-0018){ref-type="ref"}). For inoperable LSqCC patients (stage III/IV), the prognosis remains poor (Strom, Bremnes, Sundstrom, Helbekkmo, & Aasebo, [2015](#mgg3994-bib-0036){ref-type="ref"}). To evaluate the predictive values of lincRNA candidates in LSqCC staging, logistic regression was performed and ORs were calculated in 497 PT samples with definite tumor stage. Figure [2](#mgg3994-fig-0002){ref-type="fig"}e and f demonstrated that all the risk and protective lincRNA candidates were significant indicators for advance stages, except LINC01697. The ORs (95% CI) and *p*‐values for lincRNA candidates were listed in the right panel in Table [2](#mgg3994-tbl-0002){ref-type="table"} (LINC01697, *p* = .03). Figure [2](#mgg3994-fig-0002){ref-type="fig"}e showed *LINC01697* as a significant negative indicator of advance stage (logOR (95% CI) \<0). When evaluating the lincRNAs profile, we found that except above 20 risk/ protective lincRNA candidates, other 12 lincRNAs were significantly risk factor for advanced stages (logOR (95% CI) \>0); LINC01697 and other 23 lincRNAs were significantly protective factors for advanced stages (logOR (95% CI) \<0) (Figure [S2](#mgg3994-sup-0002){ref-type="supplementary-material"}).

3.5. Potential lincRNAs related to LSqCC prognosis {#mgg3994-sec-0018}
--------------------------------------------------

The prognosis for LSqCC patients was poor. KM curve for 501 included LSqCC patients' survival was exhibited in Figure [S3](#mgg3994-sup-0003){ref-type="supplementary-material"}. The 1‐year, 5‐year, 10‐year, and 14‐year survival rate were 69.59%, 47.65%, 24.27%, and 15.02% respectively (Table [S4](#mgg3994-sup-0007){ref-type="supplementary-material"}). Because all patients from TCGA‐LSqCC project underwent tumor surgery and had tumor biopsies, so the 5‐year survival rate of these patients (47.65%) was much higher than the 5‐year survival rate of lung/ bronchus cancer of 18.1% from SEER database. Among 10 protective lincRNA candidates, none of them showed protective effect against mortality; *LINC01524* was even a significant risk factor for poor survival (HR (95% CI) \>1, Table [3](#mgg3994-tbl-0003){ref-type="table"}). Among ten risk lincRNA candidates, we luckily obtained three lincRNAs (*LINC01031*, *LINC01088,* and *LINC01931*) that were also significant risk factor for poor survival (HR (95%CI) \>1, Table [3](#mgg3994-tbl-0003){ref-type="table"}). Patients were divided into lincRNA high‐level subgroup and low‐level subgroup, according to the optimal cut‐off lincRNA expression level that maximized sensitivity and specificity in predicting mortality. The KM curves and life‐test did not show a significant poorer OS for patients with *LINC01524* high‐level group (Logrank *p* = .1134, Figure [3](#mgg3994-fig-0003){ref-type="fig"}a). The 1‐year, 5‐year, and 10‐year survival rate of *LINC01524* low‐level subgroup were 0.7489, 0.5194, and 0.2897, respectively, which were not significantly higher than the 1‐year, 5‐year, and 10‐year survival rate of 0.6750, 0.4589, and 0.2252, respectively, in *LINC01524* high‐level subgroup (Logrank *p*‐value = .1134, Wilcoxon *p*‐value = .2085, Table [S5](#mgg3994-sup-0008){ref-type="supplementary-material"}A). KM curves and lifetest confirmed a significant poorer OS for patients with high level of *LINC01031* (Logrank *p* = .0244, Figure [3](#mgg3994-fig-0003){ref-type="fig"}b), *LINC01088* (Logrank *p* = .0379, Figure [3](#mgg3994-fig-0003){ref-type="fig"}c), and *LINC01931* (Logrank *p* = .0204, Figure [3](#mgg3994-fig-0003){ref-type="fig"}d) respectively. The 1‐year, 5‐year, and 10‐year survival rate of *LINC01031* low‐level subgroup were 0.7056, 0.4890, and 0.2495, respectively, which were significantly higher than the 1‐year, 5‐year, and 10‐year survival rate of 0.5892, 0.0.3549, and 0, respectively, in *LINC01031* high‐level subgroup (Logrank *p*‐value = .0244, Wilcoxon *p*‐value = .0073, Table [S5](#mgg3994-sup-0008){ref-type="supplementary-material"}B). The 1‐year, 5‐year, and 10‐year survival rate of *LINC01088* low‐level subgroup were 0.7268, 0.5003, and 0.3248, respectively, which were significantly higher than the 1‐year, 5‐year, and 10‐year survival rate of 0. 6,503, 0.4413, and 0.0984, respectively, in *LINC01088* high‐level subgroup (Logrank *p*‐value = .0379, Wilcoxon *p*‐value = .0857, Table [S5](#mgg3994-sup-0008){ref-type="supplementary-material"}C). The 1‐year, 5‐year, and 10‐year survival rate of *LINC01931* low‐level subgroup were 0.7189, 0.5080, and 0.2755, respectively, which were significantly higher than the 1‐year, 5‐year, and 10‐year survival rate of 0.6319, 0.3955, and 0, respectively, in LINC01931 high‐level subgroup (Logrank *p*‐value = .0204, Wilcoxon *p*‐value = .0693, Table [S5](#mgg3994-sup-0008){ref-type="supplementary-material"}D).

###### 

Risk of lincRNAs for mortality

  Risky LincRNAs (PT \> SN)   Univariate Cox regression   Protective LincRNAs (SN \> PT)   Univariate Cox regression                        
  --------------------------- --------------------------- -------------------------------- --------------------------- -------------------- -----
  LINC00487                   0.14 (0.03, 0.74)           .003                             LINC00307                   4.76 (0.66, 34.20)   .12
  LINC00959                   0.97 (0.69, 1.38)           .88                              LINC00491                   0.97 (0.87, 1.08)    .59
  LINC01031                   1.92 (1.07, 3.45)           .04                              LINC01063                   0.98 (0.91, 1.07)    .71
  LINC01088                   1.05 (1.01, 1.10)           .05                              LINC01385                   1.23 (0.75, 2.02)    .41
  LINC01352                   1.05 (0.64, 1.70)           .86                              LINC01448                   1.16 (0.56, 2.40)    .69
  LINC01504                   0.95 (0.69, 1.32)           .77                              LINC01524                   3.83 (1.26, 11.64)   .03
  LINC01927                   0.79 (0.28, 2.25)           .66                              LINC01697                   1.03 (0.83, 1.28)    .77
  LINC01931                   114.42 (1.05, 1.25E + 4)    .04                              LINC01719                   0.76 (0.52, 1.13)    .17
  LINC01985                   1.61 (0.63, 4.10)           .33                              LINC02026                   0.82 (0.52, 1.28)    .37
  LINC02395                   1.19 (0.10, 14.95)          .89                              LINC02315                   1.04 (0.98, 1.10)    .18
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![Potential lincRNAs related to LSqCC prognosis. (a) HR (95% CI) of 10 protective lincRNA candidates (blue), LINC01524 was significant risk factor for mortality (HR (95% CI)\<1). (b) HR (95% CI) of 10 risk lincRNA candidates (red), LINC01031, LINC01088, and LINC01931 were significantly risk factors for mortality (HR (95% CI)\>1). (c) The gene expression level of protective candidate LINC01524 in independent primary tumor samples and solid normal tissue samples. (d) The gene expression level of risk candidate LINC01031, LINC01088, and LINC01931 in independent primary tumor samples and solid normal tissue samples. (e) KM curves for LINC01524, LINC01031, LINC01088, and LINC01931 high‐expression level surbgroup and low‐expression level subgroup](MGG3-7-e994-g003){#mgg3994-fig-0003}

4. DISCUSSION {#mgg3994-sec-0019}
=============

Lung cancer is the main cause of cancer‐related deaths worldwide, accounting for 19.4% of all cancer deaths. About 1.82 million new lung cancer cases occurred globally in 2012 (Varghese, Carlos, & Shin, [2014](#mgg3994-bib-0041){ref-type="ref"}). Lung cancer is characterized by many malignant traits, such as tumor heterogeneity, aggressive proliferation, a high propensity for distant metastasis, and metabolic disorders (Ang et al., [2001](#mgg3994-bib-0001){ref-type="ref"}). Late‐stage diagnosis and the lack of effective biomarkers and therapeutic targets attribute to the low survival rate (Brown et al., [2013](#mgg3994-bib-0005){ref-type="ref"}). According to the histopathological presentation, more than eighty percent of lung cancer cases are nonsmall cell lung cancer (NSCLC) (Brown, Eraut, Trask, & Davison, [1996](#mgg3994-bib-0004){ref-type="ref"}). Despite the recent advances in multimodal treatments, the outcome of lung cancer remains unfavorable. Based on SEER database 2009--2013, the 5‐year overall survival rate of lung cancer is around 18.1%. Gene expression profiling offers a comprehensive molecular understanding of lung cancer that may grant insights into its pathophysiology and yield relevant information for subtype classification, staging, prognosis, and therapeutic decision‐making (Yu et al., [2015](#mgg3994-bib-0047){ref-type="ref"}).

While only 1%--2% of human genome contains the blueprint for protein‐coding transcripts, up to 70%--90% of human genome is transcribed into RNA (Carninci et al., [2005](#mgg3994-bib-0010){ref-type="ref"}). LincRNAs are typically co‐expressed with their neighboring gene (Cabili et al., [2011](#mgg3994-bib-0008){ref-type="ref"}). Till now, multiple strategies have been developed to target lncRNAs (Haemmerle & Gutschner, [2015](#mgg3994-bib-0017){ref-type="ref"}), including gene knockout or replacement (Sauvageau et al., [2013](#mgg3994-bib-0031){ref-type="ref"}), promoter removal or stop signal integration (Gutschner, [2015](#mgg3994-bib-0015){ref-type="ref"}; Hung et al., [2011](#mgg3994-bib-0021){ref-type="ref"}), and the use of RNA destabilization elements, such as Zinc finger nuclease (Gutschner, Baas, & Diederichs, [2011](#mgg3994-bib-0016){ref-type="ref"}), etc. For cancer treatment, there have been many successful preclinical trials. In gastric cancer, the knockdown of lncRNA *GHET1* by shRNA could suppress tumor proliferation, invasion, migration, and enhance apoptosis (Huang, Liao, Zhu, Liu, & Cai, [2017](#mgg3994-bib-0020){ref-type="ref"}). In cancer cells, LncRNA *HOTAIR* (HOX transcript antisense RNA) modulates cancer epigenome and facilitates metastasis (Gupta et al., [2010](#mgg3994-bib-0014){ref-type="ref"}); silencing *HOTAIR* is viable to suppress cancer cells (Li et al., [2013](#mgg3994-bib-0023){ref-type="ref"}). In breast and lung cancers, high level of lncRNA *BC200* (*BCYRN1*) indicates a poor prognosis (Booy, McRae, Koul, Lin, & McKenna, [2017](#mgg3994-bib-0002){ref-type="ref"}; Hu & Lu, [2015](#mgg3994-bib-0019){ref-type="ref"}). The knockdown of *BCYRN1* by siRNA could suppress cell proliferation in a broad spectrum of tumors (Booy et al., [2017](#mgg3994-bib-0002){ref-type="ref"}).

In this study, high levels of *LINC01031*, *LINC01088,* and *LINC01931* were not only valuable in tumor diagnosis, but also predicted a poor survival in LSqCC patients. Since lincRNAs always co‐express with their neighboring genes and regulate the transcription of these gene (Cabili et al., [2011](#mgg3994-bib-0008){ref-type="ref"}), so *LINC01031*, *LINC01088,* and *LINC01931* might promote LSqCC through their neighboring genes. *LINC01031* locates at 1q31.2, and the nearby protein‐coding genes includes *B3GALT2* (β‐1,3‐Galactosyltransferase 2), *CDC73* (cell division cycle 73) (Walls et al., [2017](#mgg3994-bib-0042){ref-type="ref"}), *Grx2* (glutaredoxin‐2) (Lundberg et al., [2001](#mgg3994-bib-0024){ref-type="ref"}), and *F13B* (coagulation factor XIII B subunit) (Webb, Coggan, Ichinose, & Board, [1989](#mgg3994-bib-0043){ref-type="ref"}), etc. *LINC01088* locates at 4q21.21; the adjacent genes are *NAA11* (Pang, Clark, Chan, & Rennert, [2011](#mgg3994-bib-0028){ref-type="ref"}), *GK2* and *ANTXR2* (Burgi et al., [2017](#mgg3994-bib-0007){ref-type="ref"}), etc. *LINC01931* locates at 2q23.3; this region has been suggested to be associated with human colorectal cancer in Hispanics (Schmit et al., [2016](#mgg3994-bib-0032){ref-type="ref"}). Therefore, future work should focus on lincRNA pathway investigation and treatment strategy development.

Overall, our study provided comprehensive evaluation of the lincRNA transcriptional profiles of TCGA‐LSqCC samples. We searched out the risk/ protective lincRNA candidates for LSqCC diagnosis and prognosis. *LINC01031*, *LINC01088,* and *LINC01931* might be the promising treatment targets for LSqCC patients.

5. CONCLUSION {#mgg3994-sec-0020}
=============

Compared to the normal lung tissues, LSqCC primary tumors had distinct LincRNAs transcriptional profile. Some lincRNAs could effectively predict lung malignancies. In LSqCC patients, high levels of *LINC01031*, *LINC01088,* and *LINC01931* were significantly associated with poor prognosis, suggesting potential targets for anti‐LSqCC treatment.
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